OnCo
technologiesTechnologyPhase 3

FAPI PET

FAPI PET is a PET scan that lights up the scaffolding around almost any solid tumour, including cancers the standard sugar scan misses.

Quinoline-based FAP inhibitors (FAPI-04, FAPI-46, FAPI-74) labelled with 68Ga or 18F image cancer-associated fibroblasts. Superior to FDG in pancreatic, gastric, HCC, and peritoneal disease in head-to-head series. Registrational trials for 68Ga-FAPI-46 and 18F-FAPI-74 (Sofie) are underway. Pairs with FAP-targeted radioligands.

Schematic · not to scale
Detector ring · FAP on fibroblasts · 511 keV photon pair

How it works

Small molecule binds FAP on stromal fibroblasts; rapid uptake, low background, minimal brain and liver signal.

Strengths
  • Pan-cancer, high contrast
  • No fasting needed
  • Sees desmoplastic tumours FDG misses
Limitations
  • Also uptake in fibrosis, healing, arthritis
  • Reports stroma not tumour cells
  • Not yet approved
Since
2018

Products

1top
Phase 2Theranostic pair (peptide radioligand)
FAP-2286 (177Lu / 68Ga)

A FAP-targeted theranostic pair: one version images almost any solid tumour, the other treats it with radiation.

Latest papers

top
Literature trend256 papers in the last 12 months+31% vs prior 12How this is computed
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"FAPI PET" OR ABSTRACT:"FAPI PET" OR TITLE:"FAP inhibitor PET" OR ABSTRACT:"FAP inhibitor PET" OR TITLE:"68Ga-FAPI" OR ABSTRACT:"68Ga-FAPI" OR TITLE:"fibroblast activation protein PET" OR ABSTRACT:"fibroblast activation protein PET"). Results are unfiltered search hits about FAPI PET, not a curated reading list.

Connected

35top

cancers

7
Biliary tract cancer (cholangiocarcinoma)Gastric & gastro-oesophageal junction cancerHepatocellular carcinomaMesotheliomaOesophageal cancerPancreatic ductal adenocarcinomaTriple-negative breast cancer (TNBC)

fronts

1
Imaging

technologies

2
CAR-T against stroma: fibroblasts and myeloid cellsPET (positron emission tomography)

targets

1
FAP

drugs

1
Phase 2Theranostic pair (peptide radioligand)
FAP-2286 (177Lu / 68Ga)

companies

1
SOFIE Biosciences

institutions

6
All India Institute of Medical Sciences, New DelhiEuropean Association of Nuclear MedicineHeidelberg University Hospital / NCT / DKFZPostgraduate Institute of Medical Education and Research, ChandigarhTUM Klinikum rechts der Isar / CCC MünchenUniversity Hospital Düsseldorf / CIO Düsseldorf

pathways

3
Fibroblast activation, desmoplasia & matrix stiffnessInvasion: proteases, adhesion & the invasive frontTumour microenvironment (TME)

terms

2
Cancer-associated fibroblasts (CAFs)Desmoplasia (tumour stroma)

roadmaps

2
Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PETRadiopharmaceutical roadmap: iodine → lutetium → actinium

ideas

6
A 28-day national pathway for people with a positive multi-cancer blood testA university cyclotron network with shared regulatory files for new tracersFAP theranostics as a pan-cancer stromal strategyFAPI PET as the workup for MCED positivesWhat actually holds T cells at the tumour border?When the blood test is positive, hunt for the lesion with sensitive imaging

people

3
Frederik GieselShaoli SongUwe Haberkorn